Drug intelligence / Profile preview

arterolane + piperaquine + mefloquine

Development stage: Unknown
Lead developer: Sun Pharmaceutical Industries
Modality: Small Molecules
Administration: Oral

Overview

A triple antimalarial combination therapy that combines arterolane (a synthetic ozonide antimalarial), piperaquine (a long-acting bisquinoline), and mefloquine. This combination was developed to reduce the risk of antimalarial resistance by combining a potent, rapidly cleared synthetic ozonide with two more slowly eliminated partner drugs. Clinical trials have shown it to be highly efficacious and safe for the treatment of uncomplicated falciparum malaria in children.

Targets

β-HematinCALR (Calreticulin)PfMDR1 (Plasmodium falciparum multidrug resistance protein 1)PfHRP2 (Plasmodium falciparum histidine-rich protein II)Heme

Beyond the preview

Go deeper on arterolane + piperaquine + mefloquine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on arterolane + piperaquine + mefloquine.

Explore the full profile